Compare · PRKS vs SLNO
PRKS vs SLNO
Side-by-side comparison of United Parks & Resorts Inc. (PRKS) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRKS and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 1.9x PRKS ($1.48B).
- PRKS has hit the wire 13 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 8 for PRKS).
- Company
- United Parks & Resorts Inc.
- Soleno Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.48B
- $2.76B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- 2014
- News (4w)
- 13
- 0
- Recent ratings
- 8
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest PRKS
- UNITED PARKS & RESORTS INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION
- Director Hartnett Timothy was granted 2,641 shares, increasing direct ownership by 3% to 84,019 units (SEC Form 4)
- Director Schaefer Kimberly was granted 602 shares, increasing direct ownership by 1% to 43,342 units (SEC Form 4)
- Director Narang Neha Jogani was granted 1,204 shares, increasing direct ownership by 2% to 58,580 units (SEC Form 4)
- Director Lipman Nathaniel was granted 301 shares, increasing direct ownership by 1% to 20,617 units (SEC Form 4)
- Director Gray William was granted 1,825 shares, increasing direct ownership by 2% to 78,546 units (SEC Form 4)
- Large owner Hill Path Capital Partners Co-Investment S Lp was granted 2,641 shares (SEC Form 4)
- Large owner Hill Path Capital Partners Lp was granted 2,641 shares (SEC Form 4)
- Director Chambers James P. was granted 1,592 shares, increasing direct ownership by 2% to 67,150 units (SEC Form 4)
- Chief Executive Officer Swanson Marc was granted 59,524 shares, increasing direct ownership by 15% to 447,454 units (SEC Form 4)
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)